These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
101 related articles for article (PubMed ID: 9505908)
1. Using cost-effectiveness for subsidy decisions. Glasziou P Heart; 1998 Jan; 79(1):7-8. PubMed ID: 9505908 [No Abstract] [Full Text] [Related]
2. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Use of abciximab: comparative economic data. Mark DB; Simons TA Am Heart J; 1999 May; 137(5):S123-5. PubMed ID: 10220613 [No Abstract] [Full Text] [Related]
3. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Health system perspective regarding glycoprotein IIb/IIIa inhibitor therapy. Schrogie JJ Am Heart J; 1999 May; 137(5):S126-8. PubMed ID: 10220614 [No Abstract] [Full Text] [Related]
5. Cost and outcomes analysis of abciximab use in a community teaching hospital. Abernathy GB; Hewitt KK Am J Health Syst Pharm; 1998 Dec; 55(24 Suppl 4):S35-7. PubMed ID: 9872696 [No Abstract] [Full Text] [Related]
6. Murmurs from the heart (or why the stethoscope is not an economic tool). Aristides M; Gliksman M Heart; 1998 Jan; 79(1):10-1. PubMed ID: 9518073 [No Abstract] [Full Text] [Related]
7. The use of abciximab during percutaneous coronary angioplasty reduces ischaemic events, but the cost is prohibitive. Mayosi BM; Latouf SE; Commerford PJ S Afr Med J; 1998 Feb; 88(2):130-1. PubMed ID: 9717492 [No Abstract] [Full Text] [Related]
8. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. An industry perspective on health economics studies. Anderson KM; Bala MV; Weisman HF Am Heart J; 1999 May; 137(5):S129-32. PubMed ID: 10220615 [No Abstract] [Full Text] [Related]
9. Difficulties in applying clinical trial information to the practice setting: case of a high-cost drug. Reed SD; Mullins CD; Roffman DS; Mays DA Am J Health Syst Pharm; 1998 Nov; 55(22):2409-14. PubMed ID: 9825038 [No Abstract] [Full Text] [Related]
10. Elective or selective use of abciximab? Butler R; Samani NJ Lancet; 2000 Feb; 355(9205):755. PubMed ID: 10703832 [No Abstract] [Full Text] [Related]
11. Abciximab. A pharmacoeconomic review of its use in percutaneous coronary revascularisation. Dunn CJ; Foster RH Pharmacoeconomics; 1999 Dec; 16(6):711-41. PubMed ID: 10724797 [TBL] [Abstract][Full Text] [Related]
12. Effectiveness and cost effectiveness of single bolus treatment with abciximab (Reo Pro) in preventing restenosis following percutaneous transluminal coronary angioplasty in high risk patients. Aristides M; Gliksman M; Rajan N; Davey P Heart; 1998 Jan; 79(1):12-7. PubMed ID: 9505912 [TBL] [Abstract][Full Text] [Related]
14. [Medico-economic evaluation of abciximab]. Le Pen C; Bonastre J; Pinton P Ann Cardiol Angeiol (Paris); 1999 Jan; 48(1):80-6. PubMed ID: 12555363 [TBL] [Abstract][Full Text] [Related]
15. Abciximab therapy in percutaneous intervention: economic issues in the United States. Goklaney AK; Murphy JD; Hillegass WB Eur Heart J; 1998 Apr; 19 Suppl D():D52-8. PubMed ID: 9597522 [TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of abciximab: a Canadian hospital perspective. Zed PJ; Frighetto L; Sunderji R; Marra CA Ann Pharmacother; 1998 May; 32(5):536-42. PubMed ID: 9606473 [TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of upstream versus selective glycoprotein IIb/IIIa inhibitors for acute coronary syndromes. Boersma E J Am Coll Cardiol; 2007 Jan; 49(2):276; author reply 277. PubMed ID: 17222743 [No Abstract] [Full Text] [Related]
18. Costs and effects of c7E3 in high risk PTCA patients. An indirect analysis for The Netherlands. van Hout BA; Simoons ML Eur Heart J; 1995 Nov; 16 Suppl L():81-5. PubMed ID: 8869024 [TBL] [Abstract][Full Text] [Related]
19. Abciximab therapy in percutaneous intervention: economic issues in the United States. Goklaney AK; Murphy JD; Hillegass WB Am Heart J; 1998 Apr; 135(4):S90-7. PubMed ID: 9539499 [TBL] [Abstract][Full Text] [Related]
20. [Abciximab (c7E3)--a new monoclonal antibody--from the pharmaco-economic viewpoint. Initial reports from the literature]. Sturm C Med Klin (Munich); 1996 Nov; 91(11):735-8. PubMed ID: 9036301 [No Abstract] [Full Text] [Related] [Next] [New Search]